Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

Company Overview - Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on developing and treating dermatological conditions, particularly through photodynamic therapy (PDT) [3] - The company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for the treatment of actinic keratosis (AK) and pre-cancerous skin lesions, which may progress to invasive skin cancers [3] - Biofrontera is conducting clinical trials to expand the use of its products for treating non-melanoma skin cancers and moderate to severe acne [3] Financial Results Announcement - Biofrontera Inc. will report its financial results for the three and twelve months ended December 31, 2024, on March 21, 2025 [1] - The financial results will be released before the market opens on the same day, and a conference call will be held at 10:00 AM Eastern Time [1][2] Conference Call Details - The conference call will provide an update on the fourth quarter and full year 2024 financial results [2] - Dial-in numbers for the conference call are 1-877-877-1275 for U.S. participants and 1-412-858-5202 for international participants [2]